Drug Database
ES

estradiol acetate (Menoring / Femring / Estrace VR)

✓ Approved

Actavis · ESR1 · 小分子

什么是 estradiol acetate?

estradiol acetate 是一种小分子,由Actavis研发。该药已获批,用于治疗相关适应症,给药途径:Intravaginal、Surgical Implantation。

药物档案

商品名Menoring, Femring, Estrace VR
公司Actavis
药物类别小分子
分子靶点ESR1
给药途径Intravaginal, Surgical Implantation
状态Approved

作用机制

分子靶点

estradiol acetate 作用于 1 个分子靶点:

ESR1estrogen receptor 1 (ER, ESR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

estradiol acetate 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresHormone replacement therapy✓ Approved

相关研究文献

PubMedBiology of sex differences2026-11-19

Mapping the sex-dimorphic hormonal ecosystem in osteoarthritis: non-linear interactions between androgen activity and estrogen.

Deng Bin B, Chen Ting T, Chen Qiao Q, Huang Liangzhi L et al.

The pronounced sex disparity in osteoarthritis (OA) risk implicates sex hormones, yet single-hormone studies have yielded inconsistent results. We hypothesized that androgen activity influences OA not in isolation but within a dynamic network defined by sex, menopausal status, and estradiol. We analyzed 13,848 adults from NHANES (2013-2016, 2021-2023) using an integrated framework combining complex-survey regression, two-way restricted cubic splines, generalized additive models (GAMs), and SHAP-based machine learning to model non-linear interactions across the estradiol-FAI plane. Higher free androgen index (FAI) was significantly associated with lower OA risk only in post-menopausal females (OR = 0.85, 95% CI: 0.74-0.97, P = 0.021); associations in pre-menopausal females (OR = 0.75, P = 0.145) and males (OR = 0.94, P = 0.714) were not statistically significant. Non-linear models revealed distinct regional patterns: a "buffering" pattern in post-menopausal females, where the low-estradiol/low-FAI quadrant exhibited the highest risk (GAM P = 0.002; regional synergy mean = 0.077); a "cross-over" pattern in males (GAM P = 0.042); and a flat surface in pre-menopausal females, serving as a negative control. Candidate boundaries (e.g., estradiol ≈ 2.63, FAI ≈ - 0.54 in post-menopausal females) emerged from SHAP dependence plots as hypothesis-generating indicators requiring formal validation. Machine learning confirmed that standalone predictive contributions of sex hormones were minimal (mean |SHAP| ≤ 0.0135), supporting their role as contextual modulators rather than primary drivers. Sex hormone effects on OA are context-dependent and non-linear, only discernible when examined in combination. The regional risk patterns-particularly the low-low quadrant in post-menopausal females-represent the robust core of our findings and provide a conceptual framework for understanding sex disparities through steroid interaction. Candidate boundaries are hypothesis-generating and await validation.

PMID 43053217
阅读全文 →
PubMedBMC cancer2026-11-19

Anticancer activity of Artemisia biennis L. via induction of apoptosis and regulation of BAX, BCL-2, MMP1, and MMP9 in SW480 colorectal cancer cells.

Farahani Farah F, Khafaji Batoul B, Bidgolian Fatemeh F, Ganji Shahla Mohammad SM

Colorectal cancer is one of the most common malignancies worldwide and, despite recent advances in diagnosis and treatment, it remains associated with high mortality rates. Therefore, there is a growing need for novel therapeutic strategies. Medicinal plants, as natural sources of bioactive compounds, offer promising opportunities for anticancer drug development. The present study aimed to investigate the effects of Artemisia biennis L. on the SW480 colorectal cancer cell line and its impact on the expression of apoptosis-related genes (BAX and BCL-2) and metastasis-related genes (MMP1 and MMP9). Aqueous and butanolic (polar) as well as hexane and ethyl acetate (non-polar) fractions of A. biennis were evaluated at different concentrations and exposure times for their effects on cell growth and viability. The results demonstrated that polar fractions, particularly the aqueous one, significantly reduced SW480 cell viability, with stronger effects observed at longer treatment durations. IC₅₀ values of the polar fractions were lower than those of non-polar fractions. Moreover, BAX gene expression was significantly altered in the hexane fraction, while BCL-2 expression showed notable changes in the aqueous fraction. A decrease in MMP1 and MMP9 expression was also observed in the butanol and ethyl acetate fractions, suggesting reduced migratory potential. In line with these findings, the scratch assay showed that ethyl acetate and butanolic fractions significantly inhibited SW480 cell migration, with the butanolic fraction exerting the strongest anti-migratory effect. Overall, these findings indicate that bioactive compounds from A. biennis can suppress colorectal cancer cell growth through apoptosis induction and consistent with inhibition of migration-related behavior, highlighting their potential for further investigation as anticancer agents.

PMID 43052855
阅读全文 →
PubMedHead & neck2026-11-19

Megestrol Acetate for Prevention of Weight Loss During Modern Radiotherapy in Patients With Head and Neck Cancer: A Multicenter Randomized Controlled Trial.

Muangwong Pooriwat P, Samakgarn Vatanyu V, Malasri Panlop P, Toapichattrakul Piyapasara P et al.

Weight loss is a common complication during radiotherapy for head and neck cancer and may adversely affect treatment tolerance and outcomes. We evaluated whether megestrol acetate (MA) prevents treatment-related weight loss. In this multicenter, open-label randomized controlled trial, 102 patients with non-nasopharyngeal head and neck squamous cell carcinoma undergoing radiotherapy were assigned to MA plus standard care or standard care alone. Standard care consisted of nutritional counseling, symptom management, and feeding-tube placement when clinically indicated. The primary endpoint was change in body weight from baseline to 6 weeks post-radiotherapy. At 6 weeks post-radiotherapy, the MA group showed a mean weight gain of 2.07 kg, whereas the control group lost 1.74 kg (p < 0.01). Weight gain was primarily due to increased fat mass, with no significant difference in muscle mass. Quality of life was similar between groups. MA improved weight preservation during radiotherapy and may serve as an adjunct to supportive care in head and neck cancer. ClinicalTrials.gov identifier: TCTR20240330005.

PMID 43053594
阅读全文 →
PubMedJournal of ovarian research2026-11-19

Effect of estradiol decrease from the hCG trigger day to the embryo transfer day on clinical outcomes in diminished ovarian reserve patients undergoing GnRH-antagonist protocol: a retrospective study.

Yuan Yangxuan Y, Xu Mingyang M, Meng Yicen Y, Ming Lei L et al.

Diminished ovarian reserve (DOR) represents a critical clinical challenge in assisted reproductive technology (ART), and the gonadotropin-releasing hormone (GnRH) antagonist protocol has become a commonly used regimen for DOR treatment. Although estradiol (E₂) is well established as a pivotal regulator of embryo implantation, the prognostic impact of E₂ decrease from the human chorionic gonadotropin (hCG) trigger day to the embryo transfer day on ART outcomes remains unclear in DOR patients undergoing a GnRH-antagonist protocol. This retrospective study included 570 eligible in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles of DOR patients classified as POSEIDON Groups 3 and 4, who received the GnRH-antagonist protocol at Renmin Hospital of Wuhan University between July 2019 and September 2024. The optimal cut-off value for E₂ decrease was determined using receiver operating characteristic (ROC) curve analysis. Cycles were stratified into two groups based on the cut-off: Group A (E₂ decrease < 51%) and Group B (E₂ decrease ≥ 51%). Reproductive outcomes were compared between the two groups, and multivariable binary logistic regression analysis was performed to evaluate factors associated with clinical pregnancy. Compared with the patients in non-pregnant group, the pregnant group had lower maternal age, P levels on the hCG trigger day and duration of antagonist, but had higher BMI, AFC and the proportion of patients with E₂ decrease < 51%. The logistic regression analysis indicated that the E₂ decrease group was independently associated with clinical pregnancy after multivariable adjustment. Based on the ROC-derived cut-off value, Group A had significantly higher clinical pregnancy rates [47.4% (54/114) versus 26.8% (33/123) (P < 0.01)] and embryo implantation rates [33.0% (60/182) versus 20.0% (39/195) (P < 0.01)] compared with Group B. DOR patients with an E₂ decrease of less than 51% from the hCG trigger day to the embryo transfer day showed relatively better clinical outcomes under a GnRH-antagonist protocol. Monitoring peri-transfer E₂ changes may provide complementary prognostic information.

PMID 43053039
阅读全文 →
PubMedBMC infectious diseases2026-11-19

CT-detected gynecomastia in men living with HIV: prevalence, radiological patterns, and associated factors.

Akca Veysel V, Sarı Ferda Bacaksızlar FB, Togan Turhan T

To determine the prevalence of CT-detected gynecomastia in men living with HIV, characterize its radiological subtypes, and investigate potential associations with hormonal, clinical, virological, and treatment-related factors. This retrospective observational study included 170 adult men living with HIV who underwent thoracic computed tomography (CT) examinations performed on a Somatom Definition Flash multidetector CT scanner (Siemens Healthineers, Forchheim, Germany) between January 2023 and January 2025. CT examinations were reviewed for the presence of gynecomastia, laterality, and radiological subtype (nodular, dendritic, or diffuse). Demographic characteristics, duration of HIV infection, antiretroviral treatment (ART) regimens, hormonal parameters, body mass index (BMI), CD4 and CD8 counts, CD4/CD8 ratio, HIV RNA levels, and CDC stage were obtained from medical records. Multivariable logistic regression analyses were performed to identify factors associated with gynecomastia and its radiological subtypes. The mean age of the study population was 39.7 ± 11.8 years. Gynecomastia was identified in 60 patients (35.3%), with bilateral involvement in 86.7% of cases. Bilateral disease was present in 68.2% of nodular, 84.2% of dendritic, and 95.2% of diffuse gynecomastia cases. The prevalence of gynecomastia did not differ significantly among ART regimens (p = 0.743). Estradiol levels, testosterone levels, estradiol-to-testosterone ratio, BMI, CD4 count, CD8 count, CD4/CD8 ratio, and HIV RNA levels were not independently associated with gynecomastia. In multivariable analyses, use of DTG/3TC was associated with lower odds of gynecomastia (OR: 0.115, p = 0.033). For diffuse gynecomastia, longer duration of HIV infection was independently associated with increased odds (OR: 1.419, p = 0.005). No independent predictors were identified for nodular or dendritic gynecomastia. Gynecomastia is a common incidental finding on thoracic CT in men living with HIV, affecting more than one-third of patients in this cohort. Despite the relatively young age of the study population, the prevalence was comparable to that reported in large CT-based studies from the general Turkish population. HIV duration, rather than hormonal, immunological, or virological parameters, was associated with diffuse gynecomastia, suggesting that breast tissue changes may reflect cumulative long-term effects of HIV infection and its treatment. Not applicable.

PMID 43052786
阅读全文 →
PubMedJournal of the American Chemical Society2026-11-19

Charge-to-Mass Ratio Regulation of Solvated Li+ Clusters for Ultrafast-Charging Lithium Battery Electrolytes.

Kang Guohuang G, Duan Jiachao J, Cao Yue Y, Liu Qi Q et al.

Extreme fast charging of high-energy lithium batteries is limited by coupled Li+ transport, interfacial desolvation, and electrode degradation. Here, we introduce q/Mcluster as a composition-derived prescreening descriptor, where q is the assigned charge number of the Li-centered carrier (+1 here) and Mcluster is the abundance-weighted composition mass of the cationic clusters in the four most populated solvent-separated ion-pair (SSIP) configurations. A higher q/Mcluster identifies a lower average cluster composition mass and prioritizes electrolyte candidates for transport and electrochemical testing. Guided by this descriptor, we develop a methyl acetate/fluoroethylene carbonate (MA/FEC) electrolyte that favors MA-rich solvated Li+ clusters with lower composition mass and dynamic ligand exchange, while FEC supports interphase stabilization. Simulations and experiments show weaker Li+-solvent association, a lower calculated cluster ligand-removal energy, and faster Li+ diffusion in the optimized formulation. It enables stable operation for 1000 cycles at 15C and 500 cycles in a 1 Ah pouch cell under 3C charging. Composition and cross-family controls support complementary roles for MA-regulated solvation and FEC-derived interphase stabilization, while revealing limits to a single-parameter ranking. Thus, q/Mcluster helps prioritize formulations for independent transport, interfacial, and electrochemical validation.

PMID 43053423
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多estradiol acetate